Long-term data from this registry account for the largest cohort of hypertensive patients who received renal denervation in a real-world clinical setting. This study, recently published by the European Heart Journal, confirms both the safety and efficacy of the procedure with significant and sustained reductions in both office and ambulatory blood pressure. The Global SYMPLICITY...
Patients eligible for this study suffered from hypertension, had been treated with up to 2 drugs, and presented a daytime ambulatory blood pressure ≥135/85 mmHg and <170/105 mmHg after a 4-week washout period. The study enrolled 146 patients who were randomized 1:1 to denervation treatment or a sham procedure. The reduction in daytime ambulatory systolic blood pressure was greater...
After several trials with neutral outcomes, renal denervation had been demoted for some time. However, this new study presented at EuroPCR 2018 and simultaneously published in the LANCET brings back the technique with improved devices that seem to yield improved outcomes. The study included patients with uncontrolled arterial hypertension under medical treatment. Eligible patients...
Current Perspectives on Renal Denervation. Presenters: Dr. Lucio Padilla, Argentina. Dr. Alejandro Ricalde, México. Dr. Humberto Casal, Venezuela. This video, sponsored and funded by Medtronic, was filmed during SOLACI-CACI 2017 Congress, at Hilton Buenos Aires Hotel (in Argentina). Do you want to take a look at all other SOLACI-CACI 2017 Congress Medtronic cases? Watch them We are interested in...
Courtesy of dr. Carlos Fava. At first, renal denervation enjoyed a considerable boost because, according to early studies, it lowered blood pressure (BP). However, after the results of the SYMPLICITY HTN 3 Trial its popularity decreased. Currently, the development of new technologies and greater operator experience may facilitate a change in this scenario. This...
This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet, seems to give hope to all those that still believe in renal denervation. Interim outcomes suggest that a more intensive denervation of renal arteries, carried out at the SYMPLICITY HTN-3 trial, could reduce blood pressure in patients with untreated mild to moderate hypertension....
This study included 146 patients with resistant hypertension who were medicated with an average of 5.4 drugs. Preliminary 18-month data showed a significant reduction of blood pressure values
The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal denervation safety and effectiveness in a real-world population with refractory hypertension. It plans to prospectively include a minimum of 5000 patients with refractory hypertension in 200 centers worldwide.In the 6-month analysis of the first 1000 patients included so...
Previous studies have shown that renal denervation in a 3-year period, reduced the blood pressure in resistant hypertensive patients in a sustained and meaningful way. The aim of this study was to evaluate this therapy in a larger number of patients with the control group receiving “sham” (renal angiography conscious sedation) procedure. Patients and the...
Horst Sievert 2012-08-09